These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 21803629)

  • 1. Pathogen reduction: state of reflection in Ireland.
    Murphy WG
    Transfus Clin Biol; 2011 Aug; 18(4):488-90. PubMed ID: 21803629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pathogen inactivation of platelets: organization consequences for platelet transfusion].
    Chavarin P; DePutter C; Boussoulade F; Acquart S; Vidal M; Argaud C; Fabrigli P; Garraud O
    Transfus Clin Biol; 2011 Aug; 18(4):472-7. PubMed ID: 21783400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pathogen reduction for platelets: available techniques and recent developments].
    Andreu G
    Transfus Clin Biol; 2011 Aug; 18(4):444-62. PubMed ID: 21724440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pathogen reduction for platelets: a debate].
    Moncharmont P; Py JY
    Transfus Clin Biol; 2011 Aug; 18(4):498-501. PubMed ID: 21715209
    [No Abstract]   [Full Text] [Related]  

  • 5. Pathogen-reduction systems for blood components: the current position and future trends.
    Seghatchian J; de Sousa G
    Transfus Apher Sci; 2006 Dec; 35(3):189-96. PubMed ID: 17110168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical trials for pathogen reduction in transfusion medicine: a review.
    McClaskey J; Xu M; Snyder EL; Tormey CA
    Transfus Apher Sci; 2009 Dec; 41(3):217-25. PubMed ID: 19793679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pathogen inactivation in platelet concentrates: the French experience].
    Cazenave JP
    Transfus Clin Biol; 2011 Aug; 18(4):478-84. PubMed ID: 21719338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relative safety of pooled whole-blood-derived platelets prepared by the buffy-coat method versus single-donor (apheresis) platelets.
    Vamvakas EC
    Clin Lab; 2010; 56(7-8):263-79. PubMed ID: 20857891
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bacterial detection of platelets: current problems and possible resolutions.
    Blajchman MA; Beckers EA; Dickmeiss E; Lin L; Moore G; Muylle L
    Transfus Med Rev; 2005 Oct; 19(4):259-72. PubMed ID: 16214015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternative strategies in assuring blood safety: An overview.
    Epstein JS
    Biologicals; 2010 Jan; 38(1):31-5. PubMed ID: 20110174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pathogen reduction: a clinician view].
    Socié G
    Transfus Clin Biol; 2011 Aug; 18(4):491-2. PubMed ID: 21715208
    [No Abstract]   [Full Text] [Related]  

  • 12. ABO-mismatched platelet transfusions: strategies to mitigate patient exposure to naturally occurring hemolytic antibodies.
    Josephson CD; Castillejo MI; Grima K; Hillyer CD
    Transfus Apher Sci; 2010 Feb; 42(1):83-8. PubMed ID: 20034854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands.
    Postma MJ; van Hulst M; De Wolf JT; Botteman M; Staginnus U
    Transfus Med; 2005 Oct; 15(5):379-87. PubMed ID: 16202052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands.
    Salunkhe V; van der Meer PF; de Korte D; Seghatchian J; Gutiérrez L
    Transfus Apher Sci; 2015 Feb; 52(1):19-34. PubMed ID: 25620756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on pathogen reduction technology for therapeutic plasma: an overview.
    Solheim BG; Seghatchian J
    Transfus Apher Sci; 2006 Aug; 35(1):83-90. PubMed ID: 16934528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pathogen reduction of blood components: from financial issues to possible long-term consequences].
    Canellini G; Wasserfallen JB; Tissot JD
    Transfus Clin Biol; 2011 Aug; 18(4):493-7. PubMed ID: 21719339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogen inactivation: coming of age.
    Lozano M; Cid J
    Curr Opin Hematol; 2013 Nov; 20(6):540-5. PubMed ID: 24104416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation.
    Blajchman MA
    Transfus Clin Biol; 2009 May; 16(2):70-4. PubMed ID: 19427252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogen reduction of blood components.
    Solheim BG
    Transfus Apher Sci; 2008 Aug; 39(1):75-82. PubMed ID: 18602343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Past and future approaches to assess the quality of platelets for transfusion.
    Maurer-Spurej E; Chipperfield K
    Transfus Med Rev; 2007 Oct; 21(4):295-306. PubMed ID: 17900491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.